share_log

Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Nova Mentis 開始招募加拿大衛生部首個 psilocybin 試驗
newsfile ·  2023/04/18 20:36

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has begun recruiting participants into the first-ever clinical trial investigating the effects of psilocybin on the cognitive and behavioural symptoms associated with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD).

不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2023 年 4 月 18 日)- Nova Mentis Life Science Corp.(CSE:NOVA)(FSE:HN3Q)(OTCQB:NMLSF)(“NOVA” 或 “公司”), 一家生物技術公司和神經炎症性疾病同類首創的基於裸蓋細胞素的療法和輔助診斷領域的全球領導者欣然宣佈,它已開始招募參與者參加有史以來第一項臨牀試驗,該試驗旨在研究psilocybin對脆性X綜合徵(FXS)相關的認知和行爲症狀的影響,脆性X綜合徵(FXS)是自閉症譜系障礙(ASD)的主要遺傳病因。

The 28-day study will test the safety and efficacy of NOVA's proprietary psilocybin drug (NM-1001) for the treatment of FXS, and is one of the first Health Canada approved studies allowing participants to take home psilocybin for dosing every other day.

這項爲期28天的研究將測試NOVA用於治療FXS的專有psilocybin藥物(NM-1001)的安全性和有效性,也是加拿大衛生部批准的首批允許參與者每隔一天將psilocybin帶回家給藥的研究之一。

"After achieving very positive results in NOVA's preclinical research, we are eager to begin testing our microdose psilocybin formulation on adult patients diagnosed with fragile X syndrome. Autism is the fastest growing developmental disability in the world and we believe psilocybin therapy has the potential to provide new treatment options for the symptoms associated with this unmet medical need," stated Dr. Marvin S. Hausman MD, Chairman of NOVA's Scientific Advisory Board.

“在NOVA的臨牀前研究取得非常積極的結果之後,我們渴望開始在被診斷患有脆性X綜合徵的成年患者身上測試我們的微劑量psilocybin配方。自閉症是世界上增長最快的發育障礙,我們相信psilocybin療法有可能爲與這種未得到滿足的醫療需求相關的症狀提供新的治療選擇。” NOVA科學顧問委員會主席Marvin S. Hausman博士說。

NOVA and KGK Science have partnered to conduct the Phase IIA clinical trial, which is being carried out at the KGK facility in London, Ontario, Canada. This 10-person, open-label study will assess repetitive, oral microdose psilocybin therapy for FXS. The Company intends to confirm changes in behavioural symptoms with state-of-the-art diagnostic and therapeutic mRNA and serotonin biomarker technology, combined with machine learning artificial intelligence (AI).

NOVA和KGK Science合作開展了IIA期臨牀試驗,該試驗正在加拿大安大略省倫敦的KGK工廠進行。這項由10人組成的開放標籤研究將評估FXS的重複口服微劑量psilocybin療法。該公司打算通過最先進的診斷和治療性mRNA和血清素生物標誌物技術以及機器學習人工智能(AI)來確認行爲症狀的變化。

NOVA has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used in the study.

NOVA已經完成了藥物級cGMP合成psilocybin 1.5 mg微劑量膠囊的生產,該膠囊將用於該研究。

The Company anticipates treating their first participant in Q2 2023 and having preliminary results ready later this year.

該公司預計將在2023年第二季度治療其第一位參與者,並在今年晚些時候公佈初步結果。

For more information, please click here.

欲瞭解更多信息,請點擊這裏。

To express your interest in participating in this study, please complete this eligibility questionnaire.

爲了表達您對參與這項研究的興趣,請填寫此資格問卷。

If you have questions, email participate@kgkscience.com or call 1-833-858-8359.

如果你有任何疑問,請發送電子郵件至 participate@kgkscience.com 或致電 1-833-858-8359。

About Nova Mentis Life Science Corp.

關於 Nova Mentis 生命科學公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis Life Science Corp. 是一家總部位於加拿大的生物技術公司,也是開發神經炎症性疾病診斷和基於psilocybin的療法的全球領導者。Nova是第一家在美國和歐盟因使用psilocybin治療脆性X綜合徵(FXS)而獲得孤兒藥稱號的生物技術公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

NOVA的目標是診斷和治療醫療需求未得到滿足的使人衰弱的慢性病,例如自閉症譜系障礙(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

有關公司的更多信息,請訪問或發送電子郵件至 info@novamentis.ca。

About KGK Science

關於 KGK Science

A subsidiary of Wellbeing Digital Sciences, KGK Science is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK's other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database, and collected 10 million data points. For additional information, please visit .

作爲Wellebing Digital Sciences的子公司,KGK Science是一家總部位於安大略省倫敦的領先的北美合同研究組織,主要提供高質量的臨牀研究試驗,重點是營養品和新興醫療保健產品。該公司成立於1997年,已成功幫助數百家公司進行定製設計的臨牀試驗和索賠證實策略,將產品推向全球市場。KGK的其他現有服務線包括專家監管支持和合規解決方案、參與者招聘、研究支持服務和諮詢服務。此外,該公司還出版了150多份出版物,針對40多個適應症進行了400多項臨牀試驗,在其數據庫中積累了25,000名參與者,並收集了1000萬個數據點。如需更多信息,請訪問。

On Behalf of the Board

代表董事會

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

總裁兼首席執行官威爾·拉斯坎
Nova Mentis 生命科學公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

電話:778-819-0244
免費電話:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
臉書:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成 “前瞻性陳述” 的陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致Nova Mentis Life Science的實際業績、業績或成就或該行業的發展與此類前瞻性陳述所表達或暗示的預期業績、業績或成就存在重大差異。前瞻性陳述不是歷史事實,通常但並非總是以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似表達方式來識別,或者事件或條件 “將”、“將”、“可能” 或 “應該” 發生。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論